Cancer Biology

Discussions of New Developments and Updates

Skip to content
  • Home
  • About
  • Topics
    • Statistics & Epidemiology
      • Incidence
      • Mortality
      • Prevention
      • Diet & Nutrition
    • Biology
      • Cell Cycle
      • Tumor Microenvironment
      • Angiogenesis
      • Invasion & Metastasis
      • Immortalization
      • Stem Cells
      • Heterotypic Cellular Interactions
    • Signal Transduction
      • Receptor Tyrosine Kinase Inhibitors
      • Hormone Receptors
      • Growth Receptors
    • Genetics
      • Oncogenes
      • Tumor Suppressor Genes
      • Mutations
      • Epigenetic Regulation
      • DNA Repair
    • Immunology & Immunotherapy
      • Antibodies & Conjugates
      • Checkpoint Inhibitors
      • Vaccines
      • CAR-T
    • Therapy
      • Traditional Chemotherapy
      • Hormonal
      • Surgery & Radiation
      • Rational Drug Design
      • Off-Target Effects
      • Pharmacokinetics & Pharmacodynamics
      • Resistance
  • SHU Department of Biology
Cancer Biology

Tag Archives: Eli Lilly

ImaginAB’s Minibodies for CD8+ T Cell Targeting – Select Optimal Immunotherapy Approaches

ImaginAB and Eli Lilly announced a pre-clinical collaboration to use ImaginAb’s immune imaging agent IAB22M2C to study new T-cell therapies cancer. Continue reading →

This entry was posted in active immunotherapy, Checkpoint Inhibitors, Immunology & Immunotherapy, Uncategorized, Vaccines and tagged cancer antigens, CD8+, checkpoint inhibitors, CTL, cytotoxic T-cell, Eli Lilly, ImaginAB, Minibodies on October 21, 2015 by Joseph Gulfo.

EGFR Antibody Necitumumab Recommended for Lung Cancer & Other Anti-EGFR MAb’s to Address EGFR Resistance

The Oncology Drug Advisory Committee voted (informally) to recommend approval of Lilly’s necitumumab in combination with gemcitabine and cisplatin for the first-line treatment of patients with locally advanced or metastatic squamous non–small cell lung cancer (NSCLC). Continue reading →

This entry was posted in Antibodies & Conjugates, Immunology & Immunotherapy, Mutations, Oncogenes, passive immunotherapy, Signal Transduction, Uncategorized and tagged Antibody, Cetuximab, colorectal cancer, EGFR, Eli Lilly, Erbitux, Genentech, HER, lung cancer, MEHD7945A, Necitumumab, panitumumab, Sym004, Symphogen, Vectibix on July 15, 2015 by Joseph Gulfo.


This blog is designed to provide updates in developments in cancer biology and engage in discussions about new findings in the field.

Sponsored by the Department of Biology, Seton Hall University.

@josephgulfo

Joseph Gulfo, MD Joseph Gulfo, MD ·
@josephgulfo
Artist Projects American Flag onto Swiss Alps: ‘God Bless America‘ https://t.co/vXcFilN8f5 via @BreitbartNews
View on Twitter
0
0
Joseph Gulfo, MD Joseph Gulfo, MD ·
@josephgulfo
Thoughtful FedEx Driver Sanitizes Package for Immunocompromised Girl https://t.co/iiFsybDcvP via @BreitbartNews
View on Twitter
0
2
Joseph Gulfo, MD Joseph Gulfo, MD ·
@josephgulfo
Rio‘s ‘Christ the Redeemer‘ Statue Outfitted with Doctor‘s Coat in Tribute to Healthcare Workers https://t.co/gdTGm9G1zf via @BreitbartNews
View on Twitter
0
0
Joseph Gulfo, MD Joseph Gulfo, MD ·
@josephgulfo
Four Friars Commemorate Good Friday on Jerusalem’s Via Dolorosa https://t.co/qfOaQD2N31 via @BreitbartNews
View on Twitter
0
0
Joseph Gulfo, MD Joseph Gulfo, MD ·
@josephgulfo
Coronavirus Patient: God Breathed into My Lungs and Healed Me https://t.co/9inbXBA8m9
View on Twitter
0
0
Follow @josephgulfo
Proudly powered by WordPress

Pin It on Pinterest